Aptevo Therapeutics (APVO) Competitors $0.53 -0.04 (-6.36%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. CDT, SNOA, INM, ONCO, SBFM, NBY, EVOK, TTNP, CELZ, and GENEShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Conduit Pharmaceuticals (CDT), Sonoma Pharmaceuticals (SNOA), InMed Pharmaceuticals (INM), Onconetix (ONCO), Sunshine Biopharma (SBFM), NovaBay Pharmaceuticals (NBY), Evoke Pharma (EVOK), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), and Genetic Technologies (GENE). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Conduit Pharmaceuticals Sonoma Pharmaceuticals InMed Pharmaceuticals Onconetix Sunshine Biopharma NovaBay Pharmaceuticals Evoke Pharma Titan Pharmaceuticals Creative Medical Technology Genetic Technologies Conduit Pharmaceuticals (NASDAQ:CDT) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Which has more risk and volatility, CDT or APVO? Conduit Pharmaceuticals has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.75, meaning that its share price is 475% more volatile than the S&P 500. Does the media refer more to CDT or APVO? In the previous week, Conduit Pharmaceuticals had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Conduit Pharmaceuticals and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Conduit Pharmaceuticals' score of 0.62 indicating that Aptevo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Conduit Pharmaceuticals Positive Aptevo Therapeutics Very Positive Does the MarketBeat Community favor CDT or APVO? Aptevo Therapeutics received 198 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 50.00% of users gave Aptevo Therapeutics an outperform vote. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesAptevo TherapeuticsOutperform Votes19950.00% Underperform Votes19950.00% Do insiders & institutionals believe in CDT or APVO? 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 30.9% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CDT or APVO more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -328.67% Aptevo Therapeutics N/A -488.93%-152.51% Which has preferable earnings and valuation, CDT or APVO? Conduit Pharmaceuticals has higher earnings, but lower revenue than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540K-$39.33-0.01Aptevo Therapeutics$3.11M0.25-$24.13MN/AN/A Do analysts recommend CDT or APVO? Aptevo Therapeutics has a consensus price target of $10,952.00, suggesting a potential upside of 2,066,315.09%. Given Aptevo Therapeutics' higher possible upside, analysts plainly believe Aptevo Therapeutics is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAptevo Therapeutics beats Conduit Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$773,000.00$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.4818.48Price / Sales0.25242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.166.516.774.25Net Income-$24.13M$143.21M$3.22B$248.23M7 Day Performance-23.37%1.98%1.48%0.89%1 Month Performance-46.90%6.89%3.99%3.53%1 Year Performance-99.96%-2.52%16.15%5.08% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.3531 of 5 stars$0.53-6.4%$10,952.00+2,066,315.1%-99.9%$773,000.00$3.11M0.0050Upcoming EarningsPositive NewsCDTConduit Pharmaceuticals0.342 of 5 stars$0.55-11.6%N/A-99.8%$3.65MN/A-0.013Short Interest ↑Gap DownSNOASonoma Pharmaceuticals1.0171 of 5 stars$2.22-3.5%N/A+2,291.4%$3.59M$13.97M-0.55180Positive NewsGap DownINMInMed Pharmaceuticals0.2762 of 5 stars$2.96+8.8%N/A-44.6%$3.57M$4.83M-0.2210Short Interest ↑Negative NewsONCOOnconetix1.394 of 5 stars$0.05-8.7%N/A-98.4%$3.51M$1.87M0.0012Short Interest ↓Gap DownSBFMSunshine Biopharma3.2076 of 5 stars$1.29+3.2%$15.00+1,062.8%+54.3%$3.49M$34.87M-0.013Negative NewsGap UpHigh Trading VolumeNBYNovaBay Pharmaceuticals2.5708 of 5 stars$0.60+0.0%$0.85+41.6%-79.5%$3.49M$9.78M-0.0130EVOKEvoke Pharma0.5936 of 5 stars$2.33+8.4%N/A-50.0%$3.48M$10.25M-0.214Analyst ForecastNews CoverageTTNPTitan Pharmaceuticals1.5664 of 5 stars$3.55-4.8%N/A-44.4%$3.41M$180,000.00-0.6810CELZCreative Medical Technology1.2008 of 5 stars$1.94-1.5%N/A-53.4%$3.39M$11,000.00-0.515Negative NewsGENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading Volume Related Companies and Tools Related Companies CDT Alternatives SNOA Alternatives INM Alternatives ONCO Alternatives SBFM Alternatives NBY Alternatives EVOK Alternatives TTNP Alternatives CELZ Alternatives GENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
